Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective

Background: In Type 1 diabetes (T1D), according to the most recent guidelines, the everyday glucose-lowering treatment is still restricted to the use of subcutaneous insulin, while multiple therapeutic options exist for Type 2 diabetes (T2D). Methods: For this narrative review we unsystematically sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Aberer, Felix, Pieber, Thomas R., Eckstein, Max L., Sourij, Harald, Moser, Othmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229408/
https://www.ncbi.nlm.nih.gov/pubmed/35745754
http://dx.doi.org/10.3390/pharmaceutics14061180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229408/
https://www.ncbi.nlm.nih.gov/pubmed/35745754
http://dx.doi.org/10.3390/pharmaceutics14061180

Ejemplares similares